ahlam1399
09-30-2016, 08:22 PM
UPDATE 2-Regeneron?s Eylea combination therapy fails mid-stage study
Sept 30 (Reuters) - Regeneron Pharmaceuticals Inc said a combination therapy containing its flagship eye drug,Eylea, was inferior to Eylea alone in a mid-stage trialinvolving patients with wet...http://feeds.feedburner.com/~ff/reuters/hotStocksNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/hotStocksNews?a=8Q5_zduWJUU:6Mqff9c4XF4:yIl2AUoC8z A) http://feeds.feedburner.com/~ff/reuters/hotStocksNews?i=8Q5_zduWJUU:6Mqff9c4XF4:F7zBnMyn0L o (http://feeds.reuters.com/~ff/reuters/hotStocksNews?a=8Q5_zduWJUU:6Mqff9c4XF4:F7zBnMyn0L o) http://feeds.feedburner.com/~ff/reuters/hotStocksNews?i=8Q5_zduWJUU:6Mqff9c4XF4:V_sGLiPBpW U (http://feeds.reuters.com/~ff/reuters/hotStocksNews?a=8Q5_zduWJUU:6Mqff9c4XF4:V_sGLiPBpW U)
http://feeds.feedburner.com/~r/reuters/hotStocksNews/~4/8Q5_zduWJUU
Sept 30 (Reuters) - Regeneron Pharmaceuticals Inc said a combination therapy containing its flagship eye drug,Eylea, was inferior to Eylea alone in a mid-stage trialinvolving patients with wet...http://feeds.feedburner.com/~ff/reuters/hotStocksNews?d=yIl2AUoC8zA (http://feeds.reuters.com/~ff/reuters/hotStocksNews?a=8Q5_zduWJUU:6Mqff9c4XF4:yIl2AUoC8z A) http://feeds.feedburner.com/~ff/reuters/hotStocksNews?i=8Q5_zduWJUU:6Mqff9c4XF4:F7zBnMyn0L o (http://feeds.reuters.com/~ff/reuters/hotStocksNews?a=8Q5_zduWJUU:6Mqff9c4XF4:F7zBnMyn0L o) http://feeds.feedburner.com/~ff/reuters/hotStocksNews?i=8Q5_zduWJUU:6Mqff9c4XF4:V_sGLiPBpW U (http://feeds.reuters.com/~ff/reuters/hotStocksNews?a=8Q5_zduWJUU:6Mqff9c4XF4:V_sGLiPBpW U)
http://feeds.feedburner.com/~r/reuters/hotStocksNews/~4/8Q5_zduWJUU